Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma.

Koelsche C, Kriegsmann M, Kommoss FKF, Stichel D, Kriegsmann K, Vokuhl C, Grünewald TGP, Romero-Pérez L, Kirchner T, de Alava E, Diaz-Martin J, Hartmann W, Baumhoer D, Antonescu CR, Szuhai K, Flucke U, Dirksen U, Pfister SM, Jones DTW, Mechtersheimer G, von Deimling A.

J Cancer Res Clin Oncol. 2019 May;145(5):1273-1281. doi: 10.1007/s00432-019-02895-2. Epub 2019 Mar 20.

PMID:
30895378
2.

Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma.

Dallmayer M, Li J, Ohmura S, Alba Rubio R, Baldauf MC, Hölting TLB, Musa J, Knott MML, Stein S, Cidre-Aranaz F, Wehweck FS, Romero-Pérez L, Gerke JS, Orth MF, Marchetto A, Kirchner T, Bach H, Sannino G, Grünewald TGP.

Cell Death Dis. 2019 Feb 11;10(2):116. doi: 10.1038/s41419-019-1372-0.

3.

Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity.

Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A, Dehairs J, Escalona-Noguero C, Schmieder R, Cornfield T, Charlton C, Romero-Pérez L, Rossi M, Rinaldi G, Orth MF, Boon R, Kerstens A, Kwan SY, Faubert B, Méndez-Lucas A, Kopitz CC, Chen T, Fernandez-Garcia J, Duarte JAG, Schmitz AA, Steigemann P, Najimi M, Hägebarth A, Van Ginderachter JA, Sokal E, Gotoh N, Wong KK, Verfaillie C, Derua R, Munck S, Yuneva M, Beretta L, DeBerardinis RJ, Swinnen JV, Hodson L, Cassiman D, Verslype C, Christian S, Grünewald S, Grünewald TGP, Fendt SM.

Nature. 2019 Feb;566(7744):403-406. doi: 10.1038/s41586-019-0904-1. Epub 2019 Feb 6.

PMID:
30728499
4.

Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.

Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordóñez JL, Domínguez S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frías MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler K, Seifert O, Kontermann R, Pfizenmaier K, Simón L, Fabre M, Carcaboso ÁM, Ludwig JA, de Álava E.

Clin Cancer Res. 2019 Apr 1;25(7):2228-2240. doi: 10.1158/1078-0432.CCR-18-0936. Epub 2018 Nov 12.

PMID:
30420447
5.

Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma.

Orth MF, Gerke JS, Knösel T, Altendorf-Hofmann A, Musa J, Alba-Rubio R, Stein S, Hölting TLB, Cidre-Aranaz F, Romero-Pérez L, Dallmayer M, Baldauf MC, Marchetto A, Sannino G, Knott MML, Wehweck F, Ohmura S, Li J, Hakozaki M, Kirchner T, Dandekar T, Butt E, Grünewald TGP.

Int J Cancer. 2019 Feb 15;144(4):859-867. doi: 10.1002/ijc.31903. Epub 2018 Dec 4.

PMID:
30267407
6.

Improving the management of Inherited Retinal Dystrophies by targeted sequencing of a population-specific gene panel.

Bravo-Gil N, Méndez-Vidal C, Romero-Pérez L, González-del Pozo M, Rodríguez-de la Rúa E, Dopazo J, Borrego S, Antiñolo G.

Sci Rep. 2016 Apr 1;6:23910. doi: 10.1038/srep23910.

7.

A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer.

Romero-Pérez L, Garcia-Sanz P, Mota A, Leskelä S, Hergueta-Redondo M, Díaz-Martín J, López-García MA, Castilla MA, Martínez-Ramírez A, Soslow RA, Matias-Guiu X, Moreno-Bueno G, Palacios J.

Mod Pathol. 2015 Nov;28(11):1492-503. doi: 10.1038/modpathol.2015.102. Epub 2015 Sep 18.

8.

Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer.

Díaz-Martín J, López-García MÁ, Romero-Pérez L, Atienza-Amores MR, Pecero ML, Castilla MÁ, Biscuola M, Santón A, Palacios J.

Endocr Relat Cancer. 2015 Jun;22(3):443-54. doi: 10.1530/ERC-14-0456. Epub 2015 Apr 13.

PMID:
25870251
9.

VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer.

Castilla MÁ, López-García MÁ, Atienza MR, Rosa-Rosa JM, Díaz-Martín J, Pecero ML, Vieites B, Romero-Pérez L, Benítez J, Calcabrini A, Palacios J.

Endocr Relat Cancer. 2014 Aug;21(4):587-99. doi: 10.1530/ERC-13-0485. Epub 2014 Jun 2.

PMID:
24891455
10.

ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma.

Romero-Pérez L, López-García MÁ, Díaz-Martín J, Biscuola M, Castilla MÁ, Tafe LJ, Garg K, Oliva E, Matias-Guiu X, Soslow RA, Palacios J.

Mod Pathol. 2013 Nov;26(11):1514-24. doi: 10.1038/modpathol.2013.93. Epub 2013 Jun 7.

11.

Oncogene alterations in endometrial carcinosarcomas.

Biscuola M, Van de Vijver K, Castilla MÁ, Romero-Pérez L, López-García MÁ, Díaz-Martín J, Matias-Guiu X, Oliva E, Palacios Calvo J.

Hum Pathol. 2013 May;44(5):852-9. doi: 10.1016/j.humpath.2012.07.027. Epub 2012 Nov 28.

PMID:
23199529
12.

MicroRNA-200 family modulation in distinct breast cancer phenotypes.

Castilla MÁ, Díaz-Martín J, Sarrió D, Romero-Pérez L, López-García MÁ, Vieites B, Biscuola M, Ramiro-Fuentes S, Isacke CM, Palacios J.

PLoS One. 2012;7(10):e47709. doi: 10.1371/journal.pone.0047709. Epub 2012 Oct 24.

13.

Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.

Romero-Pérez L, Castilla MÁ, López-García MÁ, Díaz-Martín J, Biscuola M, Ramiro-Fuentes S, Oliva E, Matias-Guiu X, Prat J, Cano A, Moreno-Bueno G, Palacios J.

Hum Pathol. 2013 Feb;44(2):244-54. doi: 10.1016/j.humpath.2012.05.013. Epub 2012 Sep 10.

PMID:
22974476
14.

Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma.

Castilla MÁ, Moreno-Bueno G, Romero-Pérez L, Van De Vijver K, Biscuola M, López-García MÁ, Prat J, Matías-Guiu X, Cano A, Oliva E, Palacios J.

J Pathol. 2011 Jan;223(1):72-80. doi: 10.1002/path.2802. Epub 2010 Oct 29.

PMID:
21125666
15.

Sts1 can overcome the loss of Rad23 and Rpn10 and represents a novel regulator of the ubiquitin/proteasome pathway.

Romero-Perez L, Chen L, Lambertson D, Madura K.

J Biol Chem. 2007 Dec 7;282(49):35574-82. Epub 2007 Oct 4.

Supplemental Content

Loading ...
Support Center